Navigation Links
Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
Date:4/27/2011

SEATTLE, April 28, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell, subject to customary closing conditions, approximately $16.0 million of shares of its Series 12 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to three institutional investors.  Each share of Series 12 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 2,857 shares of common stock at a conversion price of $0.35 per share of common stock, for a total of 45,634,286 shares of common stock.

In connection with the offering, the investors received warrants to purchase up to 18,253,714 shares of common stock.  The warrants have an exercise price of $0.40 per warrant share, for total potential additional proceeds to the Company of approximately $7.3 million upon exercise of the warrants for cash. The warrants are exercisable immediately and expire five years from the date of issuance.

The Company intends to use the net proceeds from the offering for general corporate purposes, which may include, among other things, paying interest on and/or retiring portions of its outstanding debt, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications and general working capital.  The Company may also use a portion of the net proceeds to fund possible investments in, or acquisitions of, complementary businesses, technologies or products.  The Company has recently engaged in limited discussions with third parties regarding such investments or acquisitions, but has no current agreements or commitments with respect to any investment or acquisition.

Shares of the Series 12 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock and have no voting ri
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... has been appointed chief financial officer of the company, ... previously executive vice president and chief financial officer of ... company.  Mr. Clerkin was part of a senior team ... in its sale to Perrigo, a pharmaceutical manufacturer, in ...
(Date:7/22/2014)... LOUIS , July 22, 2014  According to ... time their children spend on digital devices. An AOA ... ages of 10 and 17 estimate they use an ... However, a separate AOA survey of parents revealed that ... an electronic device for that same amount of time. ...
(Date:7/22/2014)... LOS ANGELES , July 22, 2014  NeuroSigma, ... sciences company focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, today announced that enrollment ... external trigeminal nerve stimulation (eTNS) as adjunctive therapy for ... trial is being conducted at the Olive View-UCLA Medical ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
(Date:7/22/2014)... Robert E. Marc, Ph.D., director of research at the ... been named by the International Society of Eye Research ... Research Foundation,s 2014 Paul Kayser International Award in Retina ... scientist who has made a significant contribution to the ... being presented this week at the ISER Biennial Meeting ...
(Date:7/22/2014)... As reported on July 17, 2014 by ABC ... her favorite beauty products, “ Botox , that’s pretty much ... Botox has changed my life” by halving the amount ... her various, daily appearances. “Suddenly my eyelids are no ... , “I think that Kelly Ripa’s response to the question ...
(Date:7/22/2014)... The 6th Latin American Conference on Lung Cancer (LALCA ... in Lima, Peru. , Lung Cancer is still the ... but worldwide. Building on the success of the previous ... national speakers will discuss the science and advances in ... malignancies worldwide and Latin America in particular. , With ...
(Date:7/22/2014)... 2014 The Entertainment Industries Council, Inc. ... educational tools and recognition activities for thousands of entertainment ... treatment and recovery. On July 24, 2014, at 8pm, ... of these resources with a special mention of the ... treatment website at the end of the show. ...
(Date:7/22/2014)... Doheny HealthDay Reporter TUESDAY, ... a minimally invasive procedure known as morcellation carries a risk ... the likelihood more clearly. Twenty-seven of every 10,000 women ... time of the procedure, researchers found, with the odds being ... performing a hysterectomy with morcellation use a power cutter to ...
Breaking Medicine News(10 mins):Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2Health News:ABC’s BLACK BOX Spotlights Mental Health and Available Resources in Upcoming Episode 2Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 2Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 3
... Health Care Budget Reform and Transparency Act of 2009 ... Government Employees, today, lauded the efforts of Congress in passing ... provided by the Department of Veterans Affairs. For more than ... VA funding process. AFGE applauds these members of Congress for ...
... will host "S,more to Love", a cocktail fundraiser on Friday, November ... benefit Birch Family Camp. , Celebrating its 20th year, the Birch ... the 5 boroughs of NYC, along with 200 volunteers for a ... located in the Hudson Valley. Throughout the year this community ...
... Health and Wellness Partners, Inc. (HWP), a wholly owned subsidiary ... line of nutraceutical products called Surge, www.feelthesurge.com ... world to develop and refine production of the product line. ... "We placed our first large production order with one of ...
... companies have been doing it for years. Why not ... thoughtful discussion in hospitals and as a way to ... secondary markets. One developer, North Carolina-based Oaks ... medical office buildings (MOBs). As such, the innovative developer ...
... in Cell Cultures and in Patients , PHILADELPHIA, ... to The Children,s Hospital of Philadelphia Research Institute will ... HIV infection -- a unique class of drugs focused ... AIDS. , Unlike many current HIV treatments, which ...
... University of Rochester Medical Center demonstrates that, for certain ... may be a cost effective treatment. The implantable ... for individuals with drug resistant hypertension. The ... Journal of Clinical Hypertension used data from ...
Cached Medicine News:Health News:VA Funding Reform Bill Clears Congress 2Health News:One Heartland Hosting: S'more to Love Cocktail Fundraiser 2Health News:Health and Wellness Partners, Inc., Says to America 'Feel the Surge' 2Health News:Health and Wellness Partners, Inc., Says to America 'Feel the Surge' 3Health News:Oaks Development Group Launches Physician Incubator Space in Palm Coast Medical Office Building 2Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 2Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 3Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 4Health News:Cost effectiveness of blood pressure device evaluated 2Health News:Cost effectiveness of blood pressure device evaluated 3
Landolt hypophysectomie instrument, spoon, bayonet-shaped, flexible....
Hardy pituitary spoon, bayonet, malleable....
... Sundt AVM Micro ... construction, non-magnetic, MRI compatible, ... coiled, high minimum closing ... of small perforating vessels ...
... Cougar is an Anterior Spinal Implant system. ... approximating that of cortical bone. The result ... requirements of anterior column support, while optimizing ... sharing design. Incorporates an anatomic design with ...
Medicine Products: